<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01477151</url>
  </required_header>
  <id_info>
    <org_study_id>16497</org_study_id>
    <nct_id>NCT01477151</nct_id>
  </id_info>
  <brief_title>Randomized Isoflurane and Sevoflurane Comparison in Cardiac Surgery</brief_title>
  <acronym>RISCCS</acronym>
  <official_title>Randomized Isoflurane and Sevoflurane Comparison in Cardiac Surgery: A Prospective Randomized Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anesthesia practice in the 21st century is increasingly outcomes-oriented and evidence-based,
      but there remain significant gaps in our knowledge, even for commonly-encountered clinical
      situations. Currently, the two most commonly used drugs used for maintenance of anesthesia in
      cardiac surgical patients are isoflurane and sevoflurane. There is a belief among many
      cardiac anesthesiologists that sevoflurane is a better cardiac anesthetic than isoflurane,
      but there is very little data to support this notion. In fact, very little is known about
      their comparative effects on important patient outcomes because there has not been a large
      head-to-head prospective randomized clinical trial. This project will supply the data
      necessary to critically compare the two anesthetics.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Current evidence supports the superiority of sevoflurane for myocardial protection during
      cardiac surgery when compared to total intravenous anesthesia with propofol. However, there
      is no evidence to suggest that sevoflurane is superior to isoflurane for myocardial
      protection during cardiac surgery. Sevoflurane may potentially reduce the rate of
      post-cardiac surgery atrial fibrillation and the time to tracheal extubation compared to
      isoflurane, but the literature is equivocal on these two important outcomes.
      Anesthesiologists still frequently use isoflurane for maintenance of cardiac anesthesia, and
      this is likely because there is substantial uncertainty about whether or not sevoflurane is
      superior to isoflurane, given the lack of head-to-head RCTs. A large, prospective, pragmatic
      RCT can ultimately assist clinicians by providing evidence of the non-inferiority (or,
      possibly the superiority) of one anesthetic compared to the other on important patient
      outcomes such as ICU length of stay, mortality, renal dysfunction, time to tracheal
      extubation after cardiac surgery, rates of clinically-important atrial fibrillation, and
      myocardial damage.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of: prolonged ICU stay (&gt;= 48 hours) OR death within 30 days of operation</measure>
    <time_frame>30 days of operation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative cardiac troponin T</measure>
    <time_frame>6 hours after admission to ICU</time_frame>
    <description>Troponin T sampled at 6 hours after admission to the ICU. The time of sampling will be recorded. The sample will be taken from an indwelling venous or arterial cannula (if one exists) or by venipuncture.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in the ICU (criteria)</measure>
    <time_frame>Participants will be followed for the duration of ICU stay, an expected average of 1 day</time_frame>
    <description>The time from admission in ICU (time 0) until the patient's transfer orders to the floor are enacted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day all-cause mortality</measure>
    <time_frame>30 days after operation</time_frame>
    <description>A participant who has died for any reason before the end of 30th day after the operation. Day 1 is the first calendar day after first being admitted to the ICU.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of tracheal intubation</measure>
    <time_frame>Participants will be followed for the duration of ICU stay, an expected average of 1 day</time_frame>
    <description>The time from being admitted to the ICU (time 0) until the patient's tracheal tube is removed for the first time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inotrope or vasopressor usage in the ICU</measure>
    <time_frame>Participants will be followed for the duration of ICU stay, an expected average of 1 day</time_frame>
    <description>A participant who is treated at any time after the first hour of their ICU stay with an inotropic or vasopressor by infusion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prolonged inotrope or vasopressor usage in the ICU</measure>
    <time_frame>Participants will be followed for the duration of ICU stay, an expected average of 1 day</time_frame>
    <description>Any patient requiring 12 or more continuous hours of any combination of inotropic or vasopressor agent (including the first hour) in the ICU.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak postoperative serum creatinine</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 1 week</time_frame>
    <description>Peak postoperative creatinine as recorded in the hospital chart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New-onset dialysis</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 1 week</time_frame>
    <description>Any patient, not previously on dialysis, requiring postoperative dialysis (hemodialysis or peritoneal dialysis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of new-onset atrial fibrillation</measure>
    <time_frame>Until end of post-operative day 4</time_frame>
    <description>We will capture the proportion of patients who have clinically significant new atrial fibrillation at any time from ICU admission until the end of POD 4. The adjudication of atrial fibrillation will be recorded by the blinded research nurse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of intra-aortic balloon pump usage</measure>
    <time_frame>Participants will be followed for the duration of ICU stay, an expected average of 1 day</time_frame>
    <description>The proportion of patients having an intra-aortic balloon pump inserted (either in the operating room or in the ICU).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in the ICU (actual)</measure>
    <time_frame>Participants will be followed for the duration of ICU stay, an expected average of 1 day</time_frame>
    <description>The time from admission in ICU (time 0) until the patient is discharged from the ICU.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in the hospital (actual)</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 1 week</time_frame>
    <description>The time from admission to the ICU until the patient is discharged home from the hospital.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readmission to ICU</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 1 week</time_frame>
    <description>Readmission to the ICU for any reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perioperative stroke</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 1 week</time_frame>
    <description>A new neurological abnormality persisting &gt; 24 hours with documentation by formal neurological examination and evidence of new brain lesions on a brain imaging study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year all-cause mortality</measure>
    <time_frame>One year after operation</time_frame>
    <description>A participant who has died for any reason within the first year after the operation. For example, if the operation takes place on June 20 2011, then mortality up to and including June 19 2012 will be counted.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">464</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Valvular Heart Disease</condition>
  <arm_group>
    <arm_group_label>sevoflurane</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>These patients will receive sevoflurane as the volatile anesthetic pre-, during-, and post-cardiopulmonary bypass at a targeted dose of 0.5-2.0 MAC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>isoflurane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>These patients will receive isoflurane as the volatile anesthetic pre-, during-, and post-cardiopulmonary bypass at a targeted dose of 0.5-2.0 MAC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Volatile anesthetic</intervention_name>
    <description>The intervention in this trial is randomization to either maintenance of anesthesia with sevoflurane or maintenance of anesthesia with isoflurane. The designated volatile anesthetic will be given at a strict minimal amount throughout the entire cardiac surgery (including cardiopulmonary bypass). This regimen (administration throughout the entire operation) has proved to have the greatest efficacy. Apart from this intervention, the anesthetic for patients participating in this trial will not be substantially different from normal practice, as the intention is to allow normal practice (with the exception of the choice of volatile anesthetic agent) to maximize the applicability and external validity of the trial. The management of anticoagulation, cardiac surgical techniques, and other aspects of the procedure will be managed in an unaltered fashion.
No IV drug infusions will be permitted until after protamine administration.</description>
    <arm_group_label>sevoflurane</arm_group_label>
    <arm_group_label>isoflurane</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be 18 years or over (There is no upper age limit to enrollment)

          -  Eligible procedures are: CABG on-pump or off-pump, single valve repair/replacement, or
             CABG/single valve combined procedures

        Exclusion Criteria:

          -  Cardiac surgeries that are not one of the included cases

          -  Planned extubation in the operating room

          -  Patients refusing blood products (vis Ã  vis blood sampling)

          -  Pregnant patients

          -  Malignant hyperthermia or documented/stated allergy to potent volatile anesthetic
             agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip M Jones, MD MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lawson Health Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital - London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2011</study_first_submitted>
  <study_first_submitted_qc>November 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2011</study_first_posted>
  <last_update_submitted>June 3, 2015</last_update_submitted>
  <last_update_submitted_qc>June 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lawson Health Research Institute</investigator_affiliation>
    <investigator_full_name>Philip Jones</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>isoflurane</keyword>
  <keyword>sevoflurane</keyword>
  <keyword>troponin</keyword>
  <keyword>anesthesia</keyword>
  <keyword>cardioprotection</keyword>
  <keyword>preconditioning</keyword>
  <keyword>cardiac surgery</keyword>
  <keyword>cardiac anesthesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
    <mesh_term>Isoflurane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

